Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms

被引:4
|
作者
Braunstein, Evan M. [1 ]
Chen, Hang [1 ]
Juarez, Felicia [1 ]
Yang, Fanghan [1 ]
Tao, Lindsay [1 ]
Makhlin, Igor [2 ]
Williams, Donna M. [1 ]
Chaturvedi, Shruti [1 ]
Pallavajjala, Aparna [3 ]
Karantanos, Theodoros [4 ]
Martin, Renan [5 ]
Wohler, Elizabeth [5 ]
Sobreira, Nara [5 ]
Gocke, Christopher D. [3 ,4 ]
Moliterno, Alison R. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Haematol, Baltimore, MD 21205 USA
[2] Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Med Oncol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, McKusick Nathans Dept Genet Med, Baltimore, MD 21205 USA
关键词
familial cancer; myeloproliferative neoplasms; germline predisposition; BREAST-CANCER; INHERITED SUSCEPTIBILITY; JAK2; HAPLOTYPE; MUTATIONS; COMMON; PREDISPOSITION; POLYMORPHISM; GENE;
D O I
10.3390/cancers13133246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Familial clustering of myeloproliferative neoplasms (MPN) is well known, with a 5- to 7-fold increased risk of MPN among first-degree relatives of MPN patients. However, the genetic susceptibility of this disease remains poorly understood. Exome sequencing of a familial MPN pedigree followed by a case-control analysis identified germline variants in the HER2/ERBB2 gene that associate with the MPN phenotype. ERBB2/HER2 is a novel susceptibility locus which contributes to cancer risk in combination with additional risk alleles. Familial cases of myeloproliferative neoplasms (MPN) are relatively common, yet few inherited risk factors have been identified. Exome sequencing of a kindred with a familial cancer syndrome characterized by both MPN and melanoma produced a germline variant in the ERBB2/HER2 gene that co-segregates with disease. To further investigate whether germline ERBB2 variants contribute to MPN predisposition, the frequency of ERBB2 variants was analyzed in 1604 cases that underwent evaluation for hematologic malignancy, including 236 cases of MPN. MPN cases had a higher frequency of rare germline ERBB2 coding variants compared to non-MPN hematologic malignancies (8.9% vs. 4.1%, OR 2.4, 95% CI: 1.4 to 4.0, p = 0.0028) as well as cases without a blood cancer diagnosis that served as an internal control (8.9% vs. 2.7%, OR 3.5, 95% CI: 1.4 to 8.3, p = 0.0053). This finding was validated via comparison to an independent control cohort of 1587 cases without selection for hematologic malignancy (8.9% in MPN cases vs. 5.2% in controls, p = 0.040). The most frequent variant identified, ERBB2 c.1960A > G; p.I654V, was present in MPN cases at more than twice its expected frequency. These data indicate that rare germline coding variants in ERBB2 are associated with an increased risk for development of MPN. The ERBB2 gene is a novel susceptibility locus which likely contributes to cancer risk in combination with additional risk alleles.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
    Stern, David F.
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2008, 13 (02) : 215 - 223
  • [42] HER2/neu (erbB2) kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGF receptors
    Wang, Shizhen Emily
    Narasanna, Archana
    Perez-Torres, Marianela
    Xiang, Bin
    Dugger, Teresa C.
    Wu, Frederick Y.
    Yang, Seungchan
    Gazdar, Adi F.
    Muthuswamy, Senthil K.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2006, 66 (08)
  • [43] HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis
    Albrecht, Thomas
    Rausch, Melina
    Roessler, Stephanie
    Albrecht, Michael
    Braun, Jana Dorothea
    Geissler, Veronika
    Mehrabi, Arianeb
    Vogel, Monika Nadja
    Pathil-Warth, Anita
    Mechtersheimer, Gunhild
    Renner, Marcus
    Rupp, Christian
    Weiss, Karl Heinz
    Busch, Elena
    Koehler, Bruno
    Springfeld, Christoph
    Schirmacher, Peter
    Goeppert, Benjamin
    BMC CANCER, 2019, 19 (01)
  • [44] HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis
    Thomas Albrecht
    Melina Rausch
    Stephanie Rössler
    Michael Albrecht
    Jana Dorothea Braun
    Veronika Geissler
    Arianeb Mehrabi
    Monika Nadja Vogel
    Anita Pathil-Warth
    Gunhild Mechtersheimer
    Marcus Renner
    Christian Rupp
    Karl Heinz Weiss
    Elena Busch
    Bruno Köhler
    Christoph Springfeld
    Peter Schirmacher
    Benjamin Goeppert
    BMC Cancer, 19
  • [45] CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy
    Turcotte, Martin
    Allard, David
    Mittal, Deepak
    Bareche, Yacine
    Buisseret, Laurence
    Jose, Vinu
    Pommey, Sandra
    Delisle, Vincent
    Loi, Sherene
    Joensuu, Heikki
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Sotiriou, Christos
    Smyth, Mark J.
    Stagg, John
    CANCER RESEARCH, 2017, 77 (20) : 5652 - 5663
  • [46] Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma
    Isharwal, Sumit
    Huang, Hongying
    Nanjangud, Gouri
    Audenet, Francois
    Chen, Ying-Bei
    Gopalan, Anuradha
    Fine, Samson W.
    Tickoo, Satish K.
    Lee, Byron H.
    Iyer, Gopa
    Chadalavada, Kalyani
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    Herr, Harry W.
    Donat, S. Machete
    Dalbagni, Guido
    Bochner, Bernard H.
    Solit, David B.
    Reuter, Victor E.
    Al-Ahmadie, Hikmat A.
    HUMAN PATHOLOGY, 2018, 77 : 63 - 69
  • [47] Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
    Özcelik, C
    Erdmann, B
    Pilz, B
    Wettschureck, N
    Britsch, S
    Hübner, N
    Chien, KR
    Birchmeier, C
    Garratt, AN
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (13) : 8880 - 8885
  • [48] Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer Close Enough?
    Burstein, Harold J.
    Schrag, Deborah
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01): : 30 - 32
  • [49] Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
    Moutafi, Myrto
    Robbins, Charles J.
    Yaghoobi, Vesal
    Fernandez, Aileen, I
    Martinez-Morilla, Sandra
    Xirou, Vasiliki
    Bai, Yalai
    Song, Yan
    Gaule, Patricia
    Krueger, Joseph
    Bloom, Kenneth
    Hill, Salisha
    Liebler, Daniel C.
    Fulton, Regan
    Rimm, David L.
    LABORATORY INVESTIGATION, 2022, 102 (10) : 1101 - 1108
  • [50] Intratumoral heterogeneity of ERBB2/HER2 expression in micropapillary urothelial carcinoma.
    Isharwal, Sumit
    Huang, Hongying
    Nanjangud, Gouri
    Audenet, Francois
    Chen, Yingbei
    Gopalan, Anuradha
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)